Department of Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People's Republic of China.
Int J Cardiol. 2013 Apr 30;165(1):76-9. doi: 10.1016/j.ijcard.2011.07.074. Epub 2011 Aug 26.
Recently, a chronic total occlusion (CTO) in the non-infarct-related artery (non-IRA) was reported as an independent predictor of clinical outcome in patients with acute ST-segment elevation myocardial infarction (STEMI). The aim of this study was to investigate the clinical significance of staged revascularization for a CTO in the non-IRA for patients with STEMI.
A total of 136 patients with acute STEMI undergoing primary percutaneous coronary intervention (PCI) received staged revascularization (ranging 7-10 days) for a CTO in the non-IRA. Cardiac mortality and major adverse cardiac events (MACE) including death, recurrent myocardial infarction, repeat revascularization, and re-hospitalization because of heart failure during 2-year follow-up were recorded.
Recanalization of totally occluded lesions in the non-IRA was successful in 87 (64%) patients for 93 lesions but failed in 49 (36%) patients. During 2-year follow-up, cardiac mortality was lower (8.0% vs. 20.4%, p = 0.036) and MACE-free survival was higher (78.2% vs. 61.2%, p = 0.042) in patients with successful than in those with failed revascularization of a CTO in the non-IRA. Multivariable analysis showed that after adjustment for possible confounders, successful recanalization of a CTO in the non-IRA was an independent predictor for 2-year cardiac mortality (HR = 0.145, 95% CI 0.047-0.446, P = 0.001) and MACE-free survival (HR = 0.430, 95%CI 0.220-0.838, P = 0.013).
Successful revascularization of a CTO in the non-IRA is associated with improved clinical outcomes in patients with STEMI undergoing primary PCI.
最近,非梗死相关动脉(non-IRA)的慢性完全闭塞(CTO)被报道为急性 ST 段抬高型心肌梗死(STEMI)患者临床预后的独立预测因素。本研究旨在探讨对急性 STEMI 患者进行非 IRA 中 CTO 分期血运重建的临床意义。
共有 136 例接受直接经皮冠状动脉介入治疗(PCI)的急性 STEMI 患者接受了非 IRA 中 CTO 的分期血运重建(时间范围为 7-10 天)。记录 2 年随访期间的心脏死亡率和主要不良心脏事件(MACE),包括死亡、再发心肌梗死、再次血运重建和因心力衰竭再次住院。
87 例(64%)患者的 93 处完全闭塞病变的非 IRA 再通成功,而 49 例(36%)患者再通失败。在 2 年随访期间,成功血运重建患者的心脏死亡率较低(8.0% vs. 20.4%,p=0.036),MACE 无事件生存率较高(78.2% vs. 61.2%,p=0.042)。多变量分析显示,在调整了可能的混杂因素后,非 IRA 中 CTO 的成功再通是 2 年心脏死亡率(HR=0.145,95%CI 0.047-0.446,P=0.001)和 MACE 无事件生存率(HR=0.430,95%CI 0.220-0.838,P=0.013)的独立预测因素。
在接受直接 PCI 的 STEMI 患者中,非 IRA 中 CTO 的成功血运重建与改善的临床结局相关。